For pharmaceutical firms, it's not just about discovering new science when it comes to finding the next big drug. But it's also about knowing where and when to search for it.
Once a successful late-stage clinical trial result is achieved with the lead drug, a promising biotechnology firm can earn a tremendous amount of value. However, by that time other pharmaceutical companies might have already been eyeing the same asset. Competition can get more and more intense, valuation may be higher, and negotiating in advance may be minimal.
That's why acquisition teams are now striving to move up the river.
It is not necessary to wait for the Phase III clinical trial data to be available to companies to look for potential targets, which can be monitored during earlier stages of development even before the data is available for Phase III trials.
This is not about predicting which biotech is going to be a winner, but about determining which is likely to be a winner. There is always a risk associated with the development of a drug and early clinical trials don't always lead to regulatory approval or commercial success. Phase II is expected to give preliminary evidence of effectiveness; Phase III is expected to yield further information on effectiveness and safety, and aid in the overall benefit-risk assessment, according to the FDA.
The chance is to leverage the data on hand at these early stages to make a selection of which businesses to pursue further.
Why Pharma Companies are looking earlier?
Today's pharmaceutical industry is facing a huge crisis in replenishing their pipelines.
In 2026, the M&A activity in biotech has picked up significantly with large pharmaceuticals companies looking to acquire biotech firms to augment existing pipelines. By July, the Financial Times had reported that 37 biotech firms worth more than $1 billion already had been acquired, surpassing last year's total.This competitive environment makes timing important.
If a pharmaceutical company discovers a promising asset only after successful Phase III results, it may be entering the process when the asset has already attracted substantial attention.
Finding a company during Phase I or Phase II pro
vides more time to:
- Understand the science
- Monitor clinical progress
- Evaluate the competitive landscape
- Assess commercial potential
- Build relationships with management
- Consider licensing or acquisition
- Compare the opportunity with internal pipeline needs
The goal is not necessarily to acquire every promising biotech. The objective is to develop a system that more effectively identifies companies deserving of a closer look.
What factors make biotech an attractive acquisition target
No one criteria can be used to determine a good acquisition target.
A great candidate is typically a person who has both clinical and scientific potential, a commercial opportunity, and a strategic fit.
A biotech, for instance, can be interesting if it has the following characteristics: a differentiated mechanism of action, early clinical evidence, a large patient population, and an asset that fills a gap in a large pharmaceutical company's pipeline.
Other factors can also increase strategic value.
A company with several related drug candidates may be more attractive than one that depends entirely on a single asset. Similarly, a platform technology that can generate multiple therapies may have greater long-term value than one drug targeting one indication.
This is why acquisition analysis needs to look at the entire company and not just its lead candidate.
Why Phase II Can Be an Important Acquisition Window
Phase II is particularly interesting because it sits between early clinical testing and larger late-stage development.
According to the FDA, Phase II studies are designed to obtain preliminary evidence of effectiveness in patients while continuing to evaluate common short-term risks. Phase III studies are generally larger and are intended to provide additional information about effectiveness and safety.
For an acquisition team, this creates an interesting balance.
A Phase II program may already have meaningful clinical evidence, but there can still be considerable uncertainty and development upside.
That means companies can evaluate questions such as:
- Does the drug show a meaningful efficacy signal?
- Is the safety profile acceptable?
- Is the mechanism supported by clinical evidence?
- Is the patient population commercially attractive?
- Does the candidate have a meaningful advantage over competitors?
- Could the drug address additional indications?
A Phase II program should never be treated as a guaranteed success. Instead, it can serve as an important point for deeper scientific and strategic diligence.
Start With the Clinical Trial
One of the best ways to evaluate a potential acquisition target is to look closely at its clinical trials.
A company announcement may state that the trial was successful, but acquisition teams require more specifics.
They should look at the design of the trial, patient population, endpoints, recruitment status, trial sites, how long it will last, what it will compare with, how much the drug is being given, and how long it will take to develop.
Variations in the number of trials can also be useful.
A company that is making quick progress from one clinical stage to another could indicate development momentum. An expansion into new indications can be a sign that management believes that there is a larger commercial opportunity.
Conversely, if the delays are frequent, the protocols change, or it is difficult to recruit or unexpected changes to the study design occurs, it may need further investigation.
What is key is not a single headline but looking at the full clinical picture.
Look Beyond Clinical Results
While clinical results are taken into account, they are just a part of the acquisition analysis.
Even a drug that has great promise for success in laboratory trials can have restricted commercial potential, for reasons such as the size of the market, the competitiveness of the market, and the strategy of the purchaser.
Acquisition teams need to consider a number of factors.
Scientific Differentiation
Has the drug discovered a novel or different way of working?
Clinical Differentiation
Does the candidate exhibit any superiority regarding efficacy, safety, rate of administration, convenience, or intended patient population?
Market Opportunity
Do there exist any major inadequacies in the treatment?
Competitive Position
How many similar programs are already being developed?
Pipeline Depth
Does the company have additional candidates beyond its lead asset?
Strategic Fit
Does this opportunity enhance an existing pharma portfolio?
This bigger picture will help to identify opportunities that would otherwise be missed.
Analyze the Whole Pipeline
While the lead product in a biotech company may draw all the attention, there is much more to be learned from its pipeline.
Drug pipeline intelligence allows acquisition teams to examine the company's complete development portfolio.
They can compare:
- Development stages
- Therapeutic areas
- Indications
- Mechanisms of action
- Biomarkers
- Clinical trial activity
- Development timelines
- Pipeline depth
Imagine a biotech with one Phase II drug and three earlier-stage programs based on the same scientific platform.
The Phase II candidate may be the immediate acquisition driver, but the additional programs could represent significant future value.
That is why pipeline analysis should be part of every serious acquisition-screening process.
Biomarkers Can Reveal Hidden Value
Biomarker information is another important part of the analysis.
A drug may appear to target a relatively narrow patient population, but a strong biomarker strategy could allow the company to identify patients who are more likely to respond.
This can support precision medicine strategies and potentially improve clinical development.
Biomarker intelligence can help acquisition teams understand:
- Which patients are being targeted
- How response is being measured
- Whether patient selection is becoming more precise
- Whether a biomarker could support additional indications
- How competing programs are approaching the same disease
This type of information can reveal value that is not immediately obvious from a company's headline pipeline.
Follow Licensing and Partnership Activity
Licensing agreements and partnerships can provide another useful signal.
When a larger pharmaceutical company enters into a deal with a smaller biotechnology company, it can indicate that the asset or technology has attracted strategic interest.
However, a licensing agreement does not automatically mean that the asset is a future acquisition target.
It should be treated as one signal among many.
Teams can monitor:
- Licensing agreements
- Research collaborations
- Co-development arrangements
- Regional partnerships
- Upfront payments
- Milestone structures
- Commercialization agreements
When these signals are combined with clinical progress and pipeline strength, they can help identify companies that deserve further attention.
Compare the Target With Competitor Pipelines
Strategic fit is one of the most important parts of acquisition analysis.
A biotech can have an excellent drug but still be a poor acquisition candidate for a particular pharmaceutical company.
The question is not simply, “Is this a good drug?”
It is also:
“Does this drug solve a problem in our pipeline?”
This means benchmarking the target with the buyer's portfolio and the overall competitive environment.
A big Pharma with a therapeutic area that lacks a successful drug could be interested in acquiring a Phase II biotech that has a complementary drug that can offer a new market.
Competitive intelligence will be able to expose these gaps.
Use AI to Find Early Signals
Manual monitoring is a challenge because of the amount of pharmaceutical information.
AI can serve acquisition teams by sifting through vast amounts of data from clinical trials, company news, scientific publications, pipelines, regulatory updates, and partnerships.AI can be used to identify patterns such as:
- Rapid pipeline progression
- Emerging therapeutic areas
- Increasing trial activity
- New mechanisms of action
- Competitor investment
- Partnership activity
But AI should be treated as a screening and decision-support tool.
It can help identify where to look. Scientific experts, clinicians, commercial teams, financial analysts, and legal teams still need to determine whether an opportunity is actually worth pursuing.
Build an Acquisition Watchlist
Instead of waiting for an acquisition opportunity to appear in the news, pharmaceutical companies can maintain a continuously updated target watchlist.
An organization which is not currently seen as an interesting acquisition target could become a lot more intriguing following the positive results from Phase II or even after regulatory approval.
With continuous surveillance, it is easier to spot such changes.
Why Waiting for Phase III Can Mean Waiting Too Long
Phase III is an important milestone in drug development, but it is not necessarily the ideal moment to begin researching an acquisition target.
By that stage, the clinical evidence is more mature, but so is the competitive attention surrounding the asset.
The company's valuation may be higher. Other pharmaceutical companies may already be involved. The target may have greater negotiating leverage.
Early intelligence does not remove the risks associated with drug development.
- What it does provide is time.
- Time to investigate the science.
- Time to compare competing assets.
- Time to understand the clinical evidence.
- Time to build relationships.
And time to decide whether a potential acquisition fits the company's long-term strategy.
How Clival Database Supports Earlier Acquisition Intelligence
Clival Database compiles various types of Life Sciences Intelligence to aid pharmaceutical and biotechnology teams assess new opportunities.
It offers Clinical Trial Intelligence, Drug Pipeline Intelligence, Sponsor Intelligence, Competitive Intelligence, Biomarker Intelligence, Mechanism of Action Intelligence, Therapeutic Area Intelligence, Market Intelligence, and Investigator & Site Intelligence.
The linked approach enables teams to transcend the need to just identify companies with drugs of promise.
They can learn about the clinical program, the sponsor, pipelines that are competing, biomarkers, mechanisms of action, and development activity.
This makes the business development and corporate strategy process more structured:
Discover, monitor, compare, evaluate and prioritize.
That's particularly useful when the purpose is to find possible acquisition targets early on before they are known to the broad market.
Comments